Multiple Myeloma in Latin America - Supporting early and equitable access to care to improve patient outcomes

Multiple Myeloma – a growing burden in Latin America

Gerard Dunleavy
Gerard Dunleavy
Senior Consultant, Economist Enterprise, Health Policy Team

21 Mar 2023

Multiple Myeloma in Latin America - Supporting early and equitable access to care to improve patient outcomes

Multiple myeloma accounts for 10% of all blood cancers and is the 2nd most common blood cancer globally. The past three decades have seen a doubling of the global incidence and mortality of myeloma with the rise being most pronounced in lower and middle-income countries (LMICs).  Countries in Latin America (LATAM), including Brazil, Colombia and Mexico, have documented rising incidence and mortality due to multiple myeloma. An aging population, increased awareness of myeloma and better case identification are contributing to the increasing incidence, while lack of timely diagnosis and inadequate access to appropriate therapies appear to be fueling the rising mortality.

“Multiple Myeloma in Latin America: Supporting early and equitable access to care to improve patient outcomes” is an Economist Enterprise white paper, commissioned by Janssen. The report provides an independent analysis of Multiple Myeloma and its growing burden in the Latin American region. The report evaluates the current care pathways for myeloma in five countries in the region (Argentina, Brazil, Colombia, Mexico and Panama), the chasm between the public and private sector, barriers for access to care, and the opportunities for improving patient outcomes.

Explore the findings in the full report, video summary and our country-level myeloma care infographics as well as a regional infographic looking at closing the public-private gap in myeloma care.

Infographics

Regional

Argentina

Brazil

Colombia

Mexico

Panama

 
 
Video
Download Full Report